Shares of Ipsen S.A. (OTCMKTS:IPSEY – Get Rating) have been given an average recommendation of “Hold” by the fourteen ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $107.22.
Several research firms have issued reports on IPSEY. Royal Bank of Canada upped their target price on shares of Ipsen from €107.00 ($115.05) to €108.00 ($116.13) in a research note on Monday, October 31st. Jefferies Financial Group began coverage on shares of Ipsen in a research note on Friday, December 2nd. They set a “buy” rating on the stock. Oddo Bhf cut shares of Ipsen from an “outperform” rating to a “neutral” rating in a research note on Friday, December 9th. JPMorgan Chase & Co. upped their target price on shares of Ipsen from C$91.00 to C$115.00 in a research note on Monday, November 21st. Finally, Morgan Stanley increased their price objective on shares of Ipsen from €84.00 ($90.32) to €86.00 ($92.47) and gave the stock an “underweight” rating in a research note on Thursday, October 13th.
Ipsen Stock Performance
IPSEY opened at $27.64 on Friday. The company’s 50-day simple moving average is $26.71 and its two-hundred day simple moving average is $25.05. Ipsen has a 52-week low of $21.17 and a 52-week high of $32.51.
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents.
- Get a free copy of the StockNews.com research report on Ipsen (IPSEY)
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy’s Stock Uptrend Set To Continue?
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.